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Somatostatin receptor scintigraphy in
patients with rheumatoid arthritis and
secondary Sjögren’s syndrome treated with
Infliximab: a pilot study
L. K. Anzola-Fuentes1,2†, M. Chianelli3†, F. Galli4,7*, A. W. J. M. Glaudemans2, L. Martin Martin5, V. Todino5,
A. Migliore6 and A. Signore2,4
Abstract
Background: Human T lymphocytes infiltrating tissues in autoimmune diseases are known to express somatostatin
receptors amongst other activation markers. In this study, we evaluated whether somatostatin receptor scintigraphy
(SRS) using a radiolabelled somatostatin analogue (99mTc-EDDA/tricine-HYNIC-tyr(3)-octreotide (99mTc-EDDA/HYNIC-TOC))
is able to detect the presence of immune-mediated processes in patients with rheumatoid arthritis and secondary
Sjögren’s syndrome. We also aimed to evaluate whether positivity to SRS was predictive of therapeutic response and if
SRS could be used for monitoring the efficacy of immunomodulatory treatment.
Methods: Eighteen patients with rheumatoid arthritis and secondary Sjögren’s syndrome not responding to
conventional treatment were recruited for treatment with infliximab, a monoclonal antibody against TNF-α. All patients
had complete blood cell count, renal and liver function tests, measurements of ESR, CRP, ANA, ENA, and anti-dsDNA
antibodies, functional salivary gland scintigraphy, labial biopsy, and ophthalmologic assessment with Schirmer’s test and
tear film break-up time (BUT). Diagnosis was made according to the revised criteria of the American-European
Consensus Group. All patients underwent SRS at baseline and after 3–6 months of therapy with infliximab. Eleven out of
18 had repeat SRS images. Images of the salivary glands and major joints were acquired 3 h after injection of 370 MBq
of 99mTc-EDDA/HYNIC-TOC. Image analysis was performed semi-quantitatively.
Results: All patients showed uptake of 99mTc-EDDA/HYNIC-TOC in the joints. Salivary glands also showed variable
radiopharmaceutical uptake in 12 out of 18 patients, but all patients showed presence of lymphocytic infiltration at labial
salivary gland biopsy. All patients, who repeated the study after treatment, showed significant reduction of somatostatin
uptake in the joints but not in the salivary glands.
Conclusions: SRS using 99mTc-EDDA/HYNIC-TOC may be a useful imaging tool to assess disease activity and extent in
patients with rheumatoid arthritis and may help to detect secondary Sjögren’s syndrome. It may also aid therapy
decision-making with anti-TNFα antibodies in the joints but not in salivary glands.
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Background
Sjögren’s syndrome (SS) and rheumatoid arthritis (RA) are
chronic inflammatory autoimmune diseases that may fre-
quently coexist in affected patients. The former is charac-
terised by a decrease in lacrimal and salivary secretion. It
can be primary (idiopathic) or secondary (when associated
with RA, ankylosing spondylitis, systemic lupus erythema-
tosus, and others). SS is particularly relevant amongst
autoimmune diseases because of its high incidence and
unknown aetiology. In particular, secondary SS may be
present in up to 30 % of patients with systemic lupus ery-
thematosus and up to 20 % of patients with RA. [1]. The
majority of affected patients are females (90 %), aged be-
tween 40 and 60 years. This might be related to the immu-
noregulatory properties of the sex hormones; however,
some genetic and environmental factors may also play a
role [2]. The causes of SS have not been elucidated yet,
but it is always characterised by a lymphocytic infiltration
in the exocrine glands (mainly the salivary and lacrimal
glands) and the presence of circulating autoantibodies that
advocate for autoimmune phenomena. Cytokines derived
from both T and B lymphocytes contribute to the destruc-
tion of glandular tissue and inflammation [3].
An important mediator of chronic inflammation in both
RA and SS is the tumour necrosis factor alpha (TNF-α)
which is a cytokine with stimulating or inhibiting activity
directly on immune cells. Impairment of TNF-α produc-
tion causes pro-inflammatory effects through the produc-
tion of many cytokines, such as interleukin-8 [4]. Given its
role in autoimmune disorders, therapeutic approaches
based on its blockage has been proposed. In particular,
anti-TNF-α monoclonal antibodies (mAbs) such as inflixi-
mab or adalimumab have been used in patients affected
by RA with positive results. Nowadays, infliximab is ap-
proved for the treatment of moderate to severe active RA,
Crohn’s disease, ulcerative colitis, ankylosing spondylitis,
psoriatic arthritis, and plaque psoriasis and is also pre-
scribed (off label) for the treatment of Behçet’s disease and
sarcoidosis [5]. However, its use in SS showed controver-
sial results and recent trials in patients have failed to con-
firm any benefit of this therapy [6]. Similarly, it has been
reported that not all RA patients respond to therapy with
anti-TNF-α antibodies [7]. This led to the hypothesis that
not all inflammatory processes in patients affected by RA
and SS are mediated by TNF-α. Therefore, non-invasive
tools to evaluate its presence in inflamed lesions would
help clinicians in selecting patients who could benefit
from infliximab therapy [8].
Over the last few years, somatostatin receptor scintig-
raphy (SRS) using somatostatin analogues has been
widely used in diagnosing different types of inflamma-
tory diseases, such as Graves’ ophthalmopathy, granu-
lomatous diseases, and rejection of cardiac allografts and
in the formation of vulnerable atherosclerotic plaques
[9]. Indeed, somatostatin has regulatory effects on im-
mune cells, associated with T cell function, and inhibits
the production of cytokines such as TNF-α, IL-1, and
IL-6 [10]. Therefore, since somatostatin receptor type 2
is overexpressed by activated lymphocytes in chronic
immune-mediated diseases [11], it could be a potential
target for peptide receptor imaging.
The aim of this study was to evaluate whether SRS is
capable of detecting the presence of immune-mediated
processes in patients with RA and secondary SS before
and after immunomodulatory therapy with infliximab. In
addition, we investigated the effect of treatment on the




octreotide (99mTc-EDDA/HYNIC-TOC) was performed
in 18 patients (2 males and 16 females; age range 18–
70 years; mean age 46.5 ± 12.2 years) affected by both
RA and secondary SS, resistant to conventional treat-
ment and diagnosed according to the revised criteria of
the American-European Consensus Group for SS [12].
In all patients, complete blood cell count, renal and liver
function tests, erythrocyte sedimentation rate (ESR), C-
reactive protein (CRP), antinuclear antibodies (ANA),
extractable nuclear antigens (ENA), anti-dsDNA anti-
bodies, labial biopsy, and ophthalmologic assessment
with Schirmer’s test and tear film break-up time (BUT)
were performed. At the time of the study, all patients
were receiving immunomodulatory drugs (cortisone
and/or cyclosporine A and/or metrothexate).
Three to 6 months after the end of the treatment with
infliximab (protocol used in the ATTRACT study) [13], the
SRS was repeated in 11 patients to evaluate the effect of
the therapy on the inflammatory process in affected joints
and salivary glands. Salivary gland scintigraphy (SGS) was
also performed to evaluate the functional status of salivary
glands pre- and post-treatment.
In addition, 20 patients with neuroendocrine tumours
(NETs), but without inflammatory lesions in joints and sal-
ivary glands, were included for 99mTc-EDDA/HYNIC-TOC
scan to investigate the uptake in those sites.
The study was approved by the Clinica Reina Sofia,
Bogotà and Regina Apostolorum Hospital, Rome and
has been performed in accordance with the ethical
standards as laid down in the 1964 Declaration of
Helsinki and its later amendments or comparable ethical
standards.
Radiopharmaceutical
99mTc-EDDA/HYNIC-TOC, a somatostatin analogue la-
belled with 99mTc was used for SRS. This radiopharma-
ceutical binds with high affinity to type 2,3, and 5
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somatostatin receptors [14] and was prepared from a
commercially available kit (99mTc-Tektrotyd, POLA-
TOM, Otwock, Poland), according to the manufacturer’s
instructions. Briefly, 740 MBq of 99mTc-pertechnetate in
0.9 % NaCl solution (pH = 7) was added to a vial con-
taining 20 μg HYNIC-Tyr3-octreotide, 40 μg stannous
chloride(II), 50 mg tricine, 10 mg mannitol, and 10 mg
ethylenediaminodiacetic acid (EDDA). The solution was
gently stirred and incubated at 80 °C for 30 minutes.
Scintigraphic imaging
Static planar images of all major joints and of the saliv-
ary glands were acquired 3 h after the i.v. injection
99mTc-EDDA/HYNIC-TOC (370 MBq) for 10 min using
a 512 × 512 matrix. Thirty minutes before the radiophar-
maceutical injection, patients were treated with
400 mg of KClO4 (Pertiroid®) to prevent the uptake
of free 99mTcO4
- possibly released by the catabolism of
99mTc-EDDA/HYNIC-TOC.
Functional sialoscintigraphy (SGS) was performed on a
separate day and less than 5 days after SRS, by i.v. injec-
tion of 99mTcO4
- (185 MBq) and acquisition of dynamic
images for 32 min using a 128 × 128 matrix. Lemon juice
(2 ml) was given 16 min after the radiopharmaceutical
injection to evaluate salivary excretion. Time activity
curves were generated to evaluate the uptake and secre-
tion pattern. Images were acquired with a double-
headed gamma camera (Philips Forte, The Netherlands)
equipped with a low-energy high-resolution collimator.
Image analysis
Evaluation of each 99mTc-EDDA/HYNIC-TOC scan was
performed visually and semi-quantitatively by two expe-
rienced nuclear medicine physicians (KAF and MC),
who were unaware of the underlying pathology, patient’s
clinical history, and the results of the other clinical pa-
rameters. Corresponding studies were compared for the
final analysis and ruled as matching or mismatching.
The SRS was semi-quantitatively analysed in joints
using a scale of 0 to 5 using the uptake in the calf
muscle as the background signal where 0 corresponds to
no uptake, less than background (T/B < 0.8); positivity
was defined by a score from 1 to 5 with a joint having a
score of 1 if uptake was detectable but lower than back-
ground (T/B between 0.8 and 1.0); 2 if uptake was simi-
lar to background (T/B between 1.0 and 1.2); 3 if uptake
was slightly higher than background (T/B between 1.2
and 1.4); 4 if uptake much higher than background (T/B
between 1.4 and 1.6); and 5 if uptake was clearly high
(T/B > 1.6). This scale provides sufficient stratification to
define the severity of the inflammatory process and
enables comparison between studies and organs. The
scores reported in tables are the average between scores
of two readers (KAF and MC), and in particular:
– n = number of positive joints (with a score greater
than 1),
– global score = the sum of all joint scores,
– severity index = global score divided by number of
positive joints.
The uptake in the salivary glands was also semi-
quantitatively analysed as follows:
– n = number of positive salivary glands,
– global score = sum of all positive glands uptake
scores (scores assigned as for joints).
In functional salivary gland scintigraphy we evaluated
the following parameters:
– Uptake score = target to background ratio of sum of
activity at 12–16 min in both parotid glands before
lemon juice administration (temporal region was
taken as background) and at 28–32 min after lemon
juice administration.
– Functional score = ratio between the uptake score
before and after administration of lemon juice.
Statistics
Differences between groups were evaluated by unpaired
Student’s t test; intra-group variations were studied using
paired Student’s t test. Regression analysis between dif-
ferent parameters was also performed.
Results
Table 1 shows the demographic characteristics and find-
ings of SRS in joints and salivary glands. All patients
showed uptake in joints with a mean global score of 17.0
(with 8.5 affected joints per patient on average with a
range of 1–20); however, only 12 patients out of 18
showed uptake in salivary glands (1 to 4 glands involved
with a range of global score from 1 to 6) despite all pa-
tients having histologically proven secondary SS.
Table 2 shows the semi-quantitative scores of SRS in
joints in the 11 patients with pre-and post-therapy
evaluation. Radiopharmaceutical uptake was significantly
reduced in joints after therapy, with a statistically signifi-
cant difference in the severity index, global score, and
number of positive joints (p = 0.009, p = 0.001, p = 0.002,
respectively).
Table 3 shows the semi-quantitative scores of SRS and
SGS in salivary glands in patients pre- and post-therapy.
SRS did not show any significant reduction of radiophar-
maceutical uptake in salivary glands after therapy (mean
global score 1.73 + 2.1 before therapy vs 1.18 + 1.25 after
therapy; p = ns), and only three patients showed a mild
improvement (patients 1, 8, and 18). SGS after therapy
with infliximab was also similar to the scan before
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Table 1 Demographic characteristics and pre-therapy findings on SRS in joints and salivary glands of patients studied
Age Gender Pre-therapy joints SRS Pre-therapy salivary glands SRS
Patient n Global score n Global score
1 18 F 13 23 4 6
2 25 F 4 18 1 2
3 40 F 5 5 2 2
4 32 F 2 2 2 2
5 45 F 1 3 1 2
6 60 F 7 13 0 0
7 22 M 10 15 0 0
8 36 F 4 8 2 4
9 29 F 4 14 0 0
10 42 F 8 14 2 6
11 40 F 10 14 0 0
12 52 F 10 20 0 0
13 54 M 10 24 1 3
14 60 F 12 22 0 0
15 62 F 8 16 2 2
16 64 F 17 29 1 2
17 39 F 20 52 2 1
18 70 F 8 14 2 4
Mean 8.5 17 1.2 1.9
±SD 4.9 11.3 1.1 1.9
Table 2 Pre-therapy and post-therapy on SRS in joints
Pre-therapy scan Post-therapy scan
Patient n Global score Severity index n Global score Severity index
1 13 23 1.8 6 8 1.3
3 5 5 1.0 4 4 1.0
4 2 2 1.0 2 2 1.0
5 1 3 3.0 1 1 1.0
6 7 13 1.9 3 4 1.3
7 10 15 1.5 6 7 1.2
8 4 8 2.0 3 4 1.3
9 4 14 3.5 2 5 2.5
12 10 20 2.0 7 13 1.9
14 12 22 1.8 5 6 1.2
18 8 14 1.8 2 3 1.5
Mean 6.9 12.6 1.9 3.7* 5.2** 1.4***
±SD 4.0 7.3 0.7 2.0 3.3 0.4
The table shows values of the number of positive joints (n), of the global score and of the severity index in the joints of the 11 patients that performed
somatostatin receptor scintigraphy (SRS) before and after treatment with Infliximab
*p = 0.002 vs pre-therapy n; **p = 0.001 vs pre-therapy global score; ***p = 0.009 vs pre-therapy severity index
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therapy (mean functional score 5.96 + 0.97 before ther-
apy vs 6.23 + 0.91 after therapy; p = ns).
ESR and CRP decreased significantly during the treat-
ment period. Infliximab was well tolerated without side
effect.
The review of the scans from the database of patients
with NETs showed no significant peri-articular uptake
around knees and shoulders with a grade score of 3 or 2
and a symmetric pattern was observed in 8 out of 20
cases, all of them older than 60 years. Uptake in hands
was observed, with a score lower than 3, with a diffuse
and asymmetric pattern located solely in the carpal
joints. In salivary glands, there was no uptake in 16 out
of 20 patients. Three patients with Hashimoto disease
had positive findings in the sub-maxillary glands but not
in the parotids. One patient had positive findings only in
parotid with an asymmetric pattern.
Discussion
Somatostatin receptors, amongst other markers, are
known to be expressed in human T lymphocytes that infil-
trate tissues in autoimmune diseases. In this study, we
have used SRS using a radiolabelled somatostatin analogue
(99mTc-EDDA/HYNIC-TOC) to detect immune-mediated
processes in patients with rheumatoid arthritis and sec-
ondary Sjögren’s syndrome. We also evaluated whether
positivity to SRS was predictive of therapeutic response
and if SRS could be used to monitor immunomodulatory
therapy with infliximab.
All our patients with arthritis and secondary SS 99mTc-
EDDA/HYNIC-TOC scans showed intense uptake with
a symmetric and focal pattern in hands, predominantly
in carpal, metacarpal, and proximal interphalangeal
joints. This finding agrees with the 2010 ACR/EULAR
criteria for diagnosis of RA in the hand [15] (Fig. 1).
Other compromised joints were knees, shoulders, and
ankles to a lesser degree. The quantitative analysis in all
patients showed a mean global score of 17, and in the 11
treated patients the mean fell from 12.6 to 5.2 after
treatment with infliximab (p = 0.001). Also, the mean se-
verity index fell from 1.9 to 1.4 after therapy (p = 0.009)
(Fig. 2). We found no correlation between joint pain or
swelling and SRS positivity. Indeed, some joints that
were apparently poorly affected showed high somato-
statin uptake and, vice versa, in some painful and swol-
len joints, we found only a moderate uptake. This
finding is in agreement with the theory that somatostatin
receptors can be overexpressed in active phases of the dis-
ease characterised by endothelial activation and lympho-
cyte infiltration in the synovial cells [16]. Nevertheless, all
patients and all positive joints showed a clinical and scinti-
graphic improvement after infliximab therapy. Thus, it
can be assumed that SRS is able to identify patients with
active disease responding to anti-TNF-α therapy.
A possible limitation of the present study is that pa-
tients with a negative SRS had not been treated with
infliximab. Therefore, we cannot conclude that negativ-
ity at SRS is related to inefficacy of the therapeutic re-
sponse. However, we can compare our results with other
published studies in which patients were not selected on
the basis of SRS positivity and the response to infliximab
therapy had a much lower rate of success [5]. This
Table 3 Pre-therapy and post-therapy findings on SRS and SGS in salivary glands
Pre-therapy scan Post-therapy scan
SRS SGS SRS SGS
Patient n Global score Functional score n Global score Functional score
1 4 6 7.5 3 3 7.5
3 2 2 5 5 2 2.5
4 2 2 4.5 2 2 4.4
5 1 1 5.4 1 1 6.3
6 0 0 6.2 0 0 6.3
7 0 0 5.2 0 0 6.1
8 2 4 5.7 2 2 6.5
9 0 0 6.5 0 0 6.7
12 0 0 7.6 0 0 7.4
14 0 0 6.2 0 0 6.4
18 2 4 5.8 2 3 5.9
Mean 1.18 1.73 5.96 1.09* 1.18* 6.23*
±SD 1.33 2.1 0.97 1.14 1.25 0–91
Table shows values of the number of positive joints (n), of the global score and of the functional score in the salivary glands of the 11 patients that performed
somatostatin receptor scintigraphy (SRS) before and after treatment with infliximab
*p = n.s. vs pre-therapy values
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finding supports the hypothesis that SRS could identify
patients with active disease who may benefit from inflixi-
mab therapy.
In patients affected by RA, SSTRs are expressed by
synovial endothelial cells and synovial macrophages. The
SSTR1 and SSTR2 subtypes have been identified on
rheumatoid synovial fibroblasts. The inhibitory effects of
somatostatin have been documented in cultures of nor-
mal activated lymphocytes and of RA synovial cells.
Somatostatin not only inhibits proliferation but also sup-
presses several mediators of inflammation including pro-
inflammatory cytokines such as TNF-α, IL-1B, and IL-8
in vitro and in vivo [17]. Somatostatin and its receptors
are produced in macrophages and lymphocytes probably
via signalling of growth factors and cytokines, and co-
activation has been demonstrated in T cells, granuloma-
tous lesions, and synovial fibroblasts from RA patients
[18]. In a study of 14 consecutive patients with RA, SRS
demonstrated uptake of 111In-pentetreotide in inflamed
joints with a lesion-related sensitivity of 74 % [19].
Adams et al. confirmed the expression of SSTR1 and
SSTR3 on inactivated endothelial cells, whereas SSTR2
is strongly expressed after activation [20]. Diffuse infil-
tration of CD4+ lymphocytes and macrophages can al-
ways be detected in affected joints, where they express
SSTR upon persistent immunological activity [21]. Stud-
ies in vitro have shown that proliferation of synovial cells
of patients suffering from RA could be inhibited by som-
atostatin. This may provide a rationale for the thera-
peutic use of long-acting somatostatin analogues for
treatment of this disease. In a clinical trial by Paran et
al., a significant clinical improvement was observed in
patients with refractory RA treated with a long-acting
somatostatin analogue [22]. SRS, therefore, holds im-
portant information not only by demonstrating the pres-
ence of inflammation but, in positive patients, could also
provide a rationale for the treatment of the disease with
unlabelled somatostatin.
Our study demonstrated that SRS scintigraphy was
positive in all patients and in several different joints but
Fig. 1 SRS of patient 17, showing high uptake of 99mTc-EDDA/HYNIC-TOC in submandibular glands, shoulders, knees, and hands with
symmetrical pattern in carpal and metacarpal joints
Fig. 2 SRS in patient number 14 before (left images) and after therapy (right images) with infliximab. Global score in hands and knees before
therapy was 22. Global score post-therapy was 6, showing good response to treatment
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not in all salivary glands. It is important to remark that
when the salivary gland pattern of uptake was compared
in SRS and SGS, a discrepancy was found in all positive
patients. This finding confirmed that the appearance of
the salivary glands in SRS is secondary to the presence
of somatostatin receptors and not to free 99mTcO4
- ,
which was reinforced by the fact that the stomach was
not visualised in any of the patients (Fig. 3).
The analysis of the scans of patients affected by NETs
and without inflammatory disease showed normal mild
to moderate uptake of the radiopharmaceutical in the
liver, spleen, renal shapes, and gastrointestinal tract.
Faint uptake of the radiopharmaceutical was observed in
the thyroid gland as reported by Duet et al. [9]. Uptake
in the stomach was not observed in any patient, thus ex-
cluding the presence of circulating free 99mTcO4
- . In
some patients (>60 years old) radiopharmaceutical up-
take was observed in carpal joints, knees, and shoulders
with a symmetrical appearance and a score equal to or
lower than 3. Vanhagen et al. postulated that this finding
could be explained by osteodegenerative disorders [19].
The absence of salivary gland uptake (16 out of 20,
80 %) was a common finding. However, an increased up-
take was observed in the salivary glands of three patients
and was related to Hashimoto’s disease. This might be
explained by the fact that the most common thyroid dis-
order found in association with SS is Hashimoto’s thy-
roiditis and that some antigens are shared by salivary
glands and thyroid gland, which could be responsible for
the association between these two pathologies [23].
In our study, only 12 patients of the 18 reported in
this study had at least one positive salivary gland at SRS.
After therapy with Infliximab (given in 11 patients, see
Table 3), only 3 patients showed an improvement of sal-
ivary SRS after therapy (1, 8, and 18) and another 3 pa-
tients showed a mild improvement at SGS (patients 5, 7,
and 8). There was no correlation seen between the
findings of the two studies in salivary glands indicating
that SRS identifies the inflamed sites mediated by som-
atostatin that did not necessarily correlate with the
structural changes evidenced at SGS. From the clinical
point of view, all patients had secondary histologically
proven SS, and all patients showed clinical improvement
of xerophthalmia and xerostomia after therapy with
infliximab. Therefore, SRS may help to identify second-
ary SS in approximately 67 % of patients with RA but
does not help in selecting patients who would respond
to anti-TNFα. This finding agrees with a recent study in
patients with primary SS in which the authors showed
that anti-TNFα therapy does not have an effect on glan-
dular and extra-glandular manifestations of SS [24]. As
far as the type of treatment is concerned, to date, there
is no standard treatment available for SS and no studies
have been performed to evaluate the effect of any ther-
apy on the function of infiltrated salivary glands.
Imaging techniques in SS include many different
methods such as ultrasound, MRI, sialography, and saliv-
ary gland scintigraphy, but none of these techniques
have a high enough sensitivity and specificity to be con-
sidered a ‘gold standard’. To date lip biopsy of the saliv-
ary glands is considered the most reliable diagnostic test
and is still the most accurate for diagnosis of SS. Sensi-
tivity and specificity of lip biopsy range from 82 to 95 %
and from 75 to 90 %, respectively [25–27]. Therefore,
only a combination of clinical, immunological, histo-
logical, functional, and morphological parameters can
help to establish a correct diagnosis of SS and to assess
the activity of the disease in order to define the most ap-
propriate treatment and to follow-up its efficacy.
In our study, we used a 99mTc-labelled somatostatin
analogue (99mTc-EDDA/HYNIC-TOC) to evaluate the
activity status of joint inflammation and associated saliv-
ary gland inflammation in a selected group of patients
with RA and secondary SS. The hypothesis behind the
Fig. 3 Comparison between SRS (left image) and SGS (right image) of salivary glands in the same patient. Images show the different uptake of the
two radiopharmaceuticals in salivary glands. There is an evident uptake only in submandibular glands at SRS, whereas all salivary glands show
uptake at SGS
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study was that SRS could be a useful tool for the workup
of these patients for therapeutic decision-making and
follow-up of biological therapies. Several hypotheses can
be proposed to explain the different behaviour of joint
and salivary gland disease. Firstly, the two may have a
different pathogenesis and natural history. Secondly, our
patients were primarily RA patients with long standing ac-
tive disease and refractory to conventional therapy. The
onset of SS might have occurred at different time points.
Finally, it is known that secondary SS is very difficult to
treat and improvement might be very poor and transient.
A possible limitation of our study could be the small
number of cases that were followed up after therapy and
by the absence of infliximab treatment of patients who
were negative for SRS. Therefore, we cannot fully assess
a correlation between positivity at SRS and therapy re-
sponse. Notably, however, in other studies in which
infliximab therapy had a much lower rate of success,
SRS were not used to select patients for therapy [18].
Conclusions
Our pilot study indicates that SRS using 99mTc-EDDA/
HYNIC-TOC is positive in joints and, to a lesser extent,
in salivary glands of patients with RA and secondary SS
who do not respond to conventional treatment. SRS may
therefore be a useful imaging tool to assess disease activ-
ity in RA and help to detect secondary SS. Given that all
positive patients showed a benefit from infliximab ther-
apy in the joints, SRS positivity might be considered as a
positive prognostic factor. We therefore suggest the use
of SRS for the selection of refractory RA patients who
may be treated with biological therapies but not as a tool
for defining treatment in secondary SS.
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